Literature DB >> 7530629

Urticaria. Recognition, causes and treatment.

A D Ormerod1.   

Abstract

The urticarias are a complex group of disorders characterised by transient whealing or swelling of the skin. Understanding the many possible causes is the first step in assessing urticaria. Allergic and drug-induced urticaria respond to removal of the cause. The physical urticarias, particularly delayed pressure urticaria and also urticarial vasculitis, require separate consideration. For the majority of patients with chronic idiopathic urticaria, nonsedating antihistamines are the mainstay of treatment. There are several to choose from, including cetirizine, astemizole, loratadine, terfenadine and acrivastine, each with its own pharmacokinetics and antiallergic properties. When these fail, histamine H2-antagonists may help either alone or in combination with H1-antagonists. Older sedative antihistamines are still useful. Ketotifen, oxatomide and azelastine have mast cell stabilising effects that are considered an advantage in treating these disorders. Second-line therapies include a wide range of drugs such as doxepin, dapsone, attenuated androgens, calcium antagonists, antimalarials, gold and methotrexate. The most effective and regularly used second-line agents are corticosteroids. These are best limited to short term crisis management, except in severe recalcitrant cases, and in patients with pressure urticaria or urticarial vasculitis. Recent work on circulating histamine releasing autoantibodies suggests that there is scope for more aggressive immunosuppression in selected patients. However, effective treatment with immunosuppression often requires plasma exchange and more toxic agents such as cyclosporin. Such treatments are only likely to be entertained in exceptional cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530629     DOI: 10.2165/00003495-199448050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  109 in total

1.  The effect of psoralen photochemotherapy (PUVA) on symptomatic dermographism.

Authors:  R A Logan; T J O'Brien; M W Greaves
Journal:  Clin Exp Dermatol       Date:  1989-01       Impact factor: 3.470

2.  Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine.

Authors:  F Lawlor; A K Black; A M Ward; R Morris; M W Greaves
Journal:  Br J Dermatol       Date:  1989-03       Impact factor: 9.302

3.  Comparison of the new antihistamine acrivastine (BW 825C) versus cyproheptadine in the treatment of idiopathic cold urticaria.

Authors:  H Neittaanmäki; J E Fräki; J R Gibson
Journal:  Dermatologica       Date:  1988

4.  Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias.

Authors:  D P Huston; R B Bressler; M Kaliner; L K Sowell; M W Baylor
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

5.  Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria.

Authors:  R M Moscati; G P Moore
Journal:  Ann Emerg Med       Date:  1990-01       Impact factor: 5.721

6.  Urticarial vasculitis: response to dapsone and colchicine.

Authors:  C Muramatsu; E Tanabe
Journal:  J Am Acad Dermatol       Date:  1985-12       Impact factor: 11.527

7.  Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human.

Authors:  R M Naclerio; A Kagey-Sobotka; L M Lichtenstein; L Freidhoff; D Proud
Journal:  Am Rev Respir Dis       Date:  1990-07

8.  Comparative inhibition profiles of three non-sedating antihistamines assessed by an extended Lewis model.

Authors:  L Shall; D A Thompson; A S Barkley; L G Millard
Journal:  Clin Exp Allergy       Date:  1992-07       Impact factor: 5.018

Review 9.  The effects of antihistamines beyond H1 antagonism in allergic inflammation.

Authors:  W A Massey; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

10.  Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria.

Authors:  J A Grant; D I Bernstein; C E Buckley; T Chu; R W Fox; R E Rocklin; W F Schoenwetter; S L Spector; C T Stafford; J E Stroh
Journal:  J Allergy Clin Immunol       Date:  1988-03       Impact factor: 10.793

View more
  3 in total

1.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 2.  Chronic urticaria: aetiology, management and current and future treatment options.

Authors:  Martina M A Kozel; Ruth A Sabroe
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Carbopol emulgel loaded with ebastine for urticaria: development, characterization, in vitro and in vivo evaluation.

Authors:  Barkat Ali Khan; Arshad Ali; Khaled M Hosny; Abdulrahman A Halwani; Alshaimaa M Almehmady; Muhammad Iqbal; Waleed S Alharbi; Walaa A Abualsunun; Rana B Bakhaidar; Samar S A Murshid; Muhammad Khalid Khan
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.